Meridian Bioscience Stock

Meridian Bioscience Net Debt

The Net Debt of Meridian Bioscience (VIVO) as of Sep 11, 2026 is -56.45 M USD. In the previous year, Net Debt was 10.23 M USD — a change of -651.89% (lower).

Net Debt

-56.45 MUSD

YoY

-651.89%

Last updated:

Net Debt of Meridian Bioscience is 2026 -56.45 M USD. Net Debt of Meridian Bioscience was 2025 10.23 M USD. It decreases by -651.89% lower compared to the previous year.

The Meridian Bioscience Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2015
-50.00 M USD
Jan 1, 2016
11.20 M USD
Jan 1, 2017
-2.50 M USD
Jan 1, 2018
-9.60 M USD
Jan 1, 2019
13.40 M USD
Jan 1, 2020
15.30 M USD
Jan 1, 2021
10.23 M USD
Jan 1, 2022
-56.45 M USD
The Meridian Bioscience Net Debt history
YEARNet DebtYoY
-56.45 MUSD-651.89%
10.23 MUSD-33.14%
15.30 MUSD+14.18%
13.40 MUSD-239.58%
-9.60 MUSD+284.00%
-2.50 MUSD-122.32%
11.20 MUSD-122.40%
-50.00 MUSD+16.28%
-43.00 MUSD
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Net Debt of Meridian Bioscience is -56.45 M USD in 2026.

Net Debt of Meridian Bioscience changed from 10.23 M USD to -56.45 M USD, representing a -651.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience